» Articles » PMID: 17880003

8-plex Quantitation of Changes in Cerebrospinal Fluid Protein Expression in Subjects Undergoing Intravenous Immunoglobulin Treatment for Alzheimer's Disease

Overview
Journal Proteomics
Date 2007 Sep 21
PMID 17880003
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

An 8-plex version of an isobaric reagent for the quantitation of proteins using shotgun methods is presented. The 8-plex version of the reagent relies on amine-labeling chemistry of peptides similar to 4-plex reagents. MS/MS reporter ions at 113, 114, 115, 116, 117, 118, 119, and 121 m/z are used to quantify protein expression. This technology which was first applied to a test mixture consisting of eight proteins and resulted in accurate quantitation, has the potential to increase throughput of analysis for quantitative shotgun proteomics experiments when compared to 2- and 4-plex methods. The technology was subsequently applied to a longitudinal study of cerebrospinal fluid (CSF) proteins from subjects undergoing intravenous Ig treatment for Alzheimer's disease. Results from this study identify a number of protein expression changes that occur in CSF after 3 and 6 months of treatment compared to a baseline and compared to a drug washout period. A visualization tool was developed for this dataset and is presented. The tool can aid in the identification of key peptides and measurements. One conclusion aided by the visualization tool is that there are differences in considering peptide-based observations versus protein-based observations from quantitative shotgun proteomics studies.

Citing Articles

Animal Wellness: The Power of Multiomics and Integrative Strategies: Multiomics in Improving Animal Health.

Choudhary R, Kumar B V S, Sekhar Mukhopadhyay C, Kashyap N, Sharma V, Singh N Vet Med Int. 2024; 2024:4125118.

PMID: 39484643 PMC: 11527549. DOI: 10.1155/2024/4125118.


Deciphering Cancer Complexity: Integrative Proteogenomics and Proteomics Approaches for Biomarker Discovery.

Rao R, Gulfishan M, Kim M, Kashyap M Methods Mol Biol. 2024; 2859:211-237.

PMID: 39436604 DOI: 10.1007/978-1-0716-4152-1_12.


Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics.

Zou M, Zhou H, Gu L, Zhang J, Fang L Biology (Basel). 2024; 13(8).

PMID: 39194493 PMC: 11352082. DOI: 10.3390/biology13080555.


A Tutorial Review of Labeling Methods in Mass Spectrometry-Based Quantitative Proteomics.

Wang Z, Liu P, Li L ACS Meas Sci Au. 2024; 4(4):315-337.

PMID: 39184361 PMC: 11342459. DOI: 10.1021/acsmeasuresciau.4c00007.


Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy.

Mitsunaga S, Okumura N, Takei T, Takao T, Tsubouchi H, Nakata K Sci Rep. 2024; 14(1):14207.

PMID: 38902359 PMC: 11190254. DOI: 10.1038/s41598-024-65093-2.


References
1.
Lee K . Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol. 2001; 19(6):217-22. DOI: 10.1016/s0167-7799(01)01639-0. View

2.
Finehout E, Franck Z, Choe L, Relkin N, Lee K . Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2006; 61(2):120-9. DOI: 10.1002/ana.21038. View

3.
Weksler M, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P . Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002; 37(7):943-8. DOI: 10.1016/s0531-5565(02)00029-3. View

4.
McDonald W, Yates 3rd J . Shotgun proteomics: integrating technologies to answer biological questions. Curr Opin Mol Ther. 2003; 5(3):302-9. View

5.
Puchades M, Hansson S, Nilsson C, Andreasen N, Blennow K, Davidsson P . Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003; 118(1-2):140-6. DOI: 10.1016/j.molbrainres.2003.08.005. View